1,047 results match your criteria: "Institute of Hematology and Blood Transfusion[Affiliation]"

Background: Treatment of patients diagnosed with myelodysplastic neoplasms (MDS) is difficult and the outcome is still limited, especially in developing countries. We conducted this study in order to share some experience in treating patients diagnosed with MDS in developing countries.

Methods: This was a retrospective study that included 32 patients with newly MDS.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the relationship between graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) effects in acute myeloid leukemia (AML) patients after stem-cell transplantation (SCT), specifically comparing standard and post-transplant cyclophosphamide (PTCy) methods.
  • Results show that while GVHD correlates with lower relapse rates and higher non-relapse mortality (NRM) and lower overall survival (OS) in standard cases, following PTCy, GVHD does not reduce relapse.
  • The findings indicate that although GVHD remains a significant factor in SCT outcomes, its role changes depending on the type of prophylaxis used, particularly diminishing its association with relapse in the PTC
View Article and Find Full Text PDF

In the field of healthcare, quality and efficiency are of paramount importance to ensure the provision of safe and reliable diagnostic services. Blood screening laboratories play a critical role in detecting and preventing the spread of infectious diseases, ensuring the safety of blood transfusions, and supporting medical diagnoses. To enhance the quality of processes in such laboratories, the Six Sigma methodology has gained significant recognition for its ability to systematically identify and minimize variations, thereby improving overall efficiency and reducing errors.

View Article and Find Full Text PDF

Cardiogenic shock (CS) is a devastating and fatal complication of acute myocardial infarction (AMI). CS can affect the pharmacokinetics and pharmacodynamics of medications. The unique properties of cangrelor make it the optimal P2Y12 inhibitor for CS-AMI, in terms of both efficacy and safety.

View Article and Find Full Text PDF

Purpose: The use of inotuzumab ozogamicin (InO), a conjugated anti-CD22 monoclonal antibody, is becoming a promising frontline treatment for older patients with ALL.

Patients And Methods: EWALL-INO is an open-label prospective multicenter phase II trial (ClinicalTrials.gov identifier: NCT03249870).

View Article and Find Full Text PDF
Article Synopsis
  • * Treatment with hypomethylating agents like azacytidine is common, but patient responses vary, necessitating better understanding through genetic and epigenetic analysis, particularly RNA methylation.
  • * Recent research focused on RNA methylation in MDS patients to determine factors that distinguish responders from non-responders to azacytidine, suggesting that analyzing the methylome can provide more accurate prognostic insights for high-grade MDS patients.
View Article and Find Full Text PDF

Despite new treatment strategies, graft-versus-host disease (GvHD) remains a formidable complication after allogeneic hematopoietic stem cell transplantation (HSCT). This study aimed to investigate the impact of polymorphisms and expression of MICA and NKG2D receptor on the development of GvHD in allogeneic HSCT recipients. Soluble MICA (sMICA) concentration was measured in serum collected 30 days after transplantation and the genetic variability of MICA and NKG2D genes was evaluated.

View Article and Find Full Text PDF

Coeliac disease (CD) is an autoimmune disorder caused by the ingestion of gluten-containing grains. One of the prerequisites for the development of the disease is the presence of specific combinations of HLA alleles at the DQA1 and DQB1 loci. The HLA test is a supportive diagnostic test.

View Article and Find Full Text PDF

Introduction: Inherited bone marrow failure (IBMF) syndromes are caused by mutations forming pathologic germline variants resulting in the production of defective hematopoietic stem cells (HSC) and in congenital failure in the production of one or more blood lineages. An acquisition of subsequent somatic mutations is determining further course of the disease. Nevertheless, a certain number of patients with IBMF may escape correct diagnosis in childhood, especially those with mild cytopenia and minimal clinical features without non-hematologic symptoms.

View Article and Find Full Text PDF

Purpose: To determine the optimal daunorubicin dose and number of 7 + 3 induction cycles in newly diagnosed AML, this randomized controlled trial compared a once daily dose of 60 mg/m with 90 mg/m daunorubicin in the first 7 + 3 induction and one versus two cycles of 7 + 3 induction.

Patients And Methods: Patients age 18-65 years with newly diagnosed AML were randomly assigned to 60 versus 90 mg/m daunorubicin once daily plus cytarabine. Patients with marrow blasts below 5% on day 15 after first induction were randomly assigned to receive a second induction cycle or no second induction cycle.

View Article and Find Full Text PDF

Interferometric excitation fluorescence lifetime imaging microscopy.

Nat Commun

September 2024

Faculty of Mathematics and Physics, Institute of Physics, Charles University, Prague, Czech Republic.

Fluorescence lifetime imaging microscopy (FLIM) is a well-established technique with numerous imaging applications. Yet, one of the limitations of FLIM is that it only provides information about the emitting state. Here, we present an extension of FLIM by interferometric measurement of fluorescence excitation spectra.

View Article and Find Full Text PDF

Background: The mechanistic target of rapamycin (mTOR) is a crucial regulator of cell metabolic activity. It forms part of several distinct protein complexes, particularly mTORC1 and mTORC2. The lack of specific inhibitors still hampers the attribution of mTOR functions to these complexes.

View Article and Find Full Text PDF

The best donor option for acute myeloid leukemia (AML) patients lacking an HLA-matched donor has remained intensively debated. We herein report the results of a large retrospective registry study comparing hematopoietic cell transplantation (HCT) outcomes between double-unit umbilical cord blood transplantation (dCBT, n = 209) versus 9/10 HLA-matched unrelated donor (UD) with posttransplant cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) prophylaxis (UD 9/10, n = 270) in patients with AML in first complete remission (CR1). Inclusion criteria consisted of adult patient, AML in CR1 at transplantation, either peripheral blood stem cells (PBSC) from UD 9/10 with PTCy as GVHD prophylaxis or dCBT without PTCy, transplantation between 2013 and 2021, and no in vivo T-cell depletion.

View Article and Find Full Text PDF

Background: The non-viral production of CAR-T cells through electroporation of transposon DNA plasmids is an alternative approach to lentiviral/retroviral methods. This method is particularly suitable for early-phase clinical trials involving novel types of CAR-T cells. The primary disadvantage of non-viral methods is the lower production efficiency compared to viral-based methods, which becomes a limiting factor for CAR-T production, especially in chemotherapy-pretreated lymphopenic patients.

View Article and Find Full Text PDF

Acute myeloid leukemia (AML) is the most common form of acute leukemia diagnosed in adults. Despite advances in medical care, the treatment of AML still faces many challenges, such as treatment-related toxicities, that limit the use of high-intensity chemotherapy, especially in elderly patients. Currently, various immunotherapeutic approaches, that is, CAR-T cells, BiTEs, and immune checkpoint inhibitors, are being tested in clinical trials to prolong remission and improve the overall survival of AML patients.

View Article and Find Full Text PDF

Imatinib therapy of chronic myeloid leukemia significantly reduces carnitine cell intake, resulting in adverse events.

Mol Metab

October 2024

Institute of Hematology and Blood Transfusion, Prague, Czech Republic; Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic. Electronic address:

Objective: A prominent, safe and efficient therapy for patients with chronic myeloid leukemia (CML) is inhibiting oncogenic protein BCR::ABL1 in a targeted manner with imatinib, a tyrosine kinase inhibitor. A substantial part of patients treated with imatinib report skeletomuscular adverse events affecting their quality of life. OCTN2 membrane transporter is involved in imatinib transportation into the cells.

View Article and Find Full Text PDF
Article Synopsis
  • A study analyzed outcomes of allogeneic hematopoietic stem cell transplantation (HSCT) for favorable risk Acute Myeloid Leukemia (AML) patients in complete remission across three time periods, involving 1850 patients.
  • Over the years from 2015 to 2021, older patients (≥60 years) and those with NPM1FLT3 diagnoses increased, while Haploidentical transplants also grew significantly.
  • The study found a reduction in chronic graft-versus-host disease and improved GVHD-free, relapse-free survival for patients transplanted after 2010 compared to earlier periods, though other outcomes showed no significant changes during the study period.
View Article and Find Full Text PDF

Navigating the Asia-Pacific region plasma therapies landscape: Insights from the 2023 Asia-Pacific Plasma Leaders' Network meetings.

Vox Sang

November 2024

Training and Overseas Information, Blood Service Headquarters, Japanese Red Cross Society (JRCS), Tokyo, Japan.

Article Synopsis
  • The Asia-Pacific Plasma Leaders' Network (APPLN) aims to tackle the shortage of plasma-derived medicinal products (PDMPs) in low- and middle-income countries (LMICs) by facilitating expert collaboration and addressing challenges in availability and affordability.
  • Despite recognition from the WHO regarding the importance of PDMPs for treating life-threatening diseases, many LMICs face issues like insufficient plasma supplies and lack of technical resources for fractionation.
  • Recent discussions highlighted the urgent need for improved domestic plasma collection and established fractionation programs, emphasizing that tailored, collaborative strategies are vital for enhancing access to PDMPs in the region.
View Article and Find Full Text PDF

We compared transplantation (HSCT) outcomes in AML patients undergoing HSCT with post-transplant cyclophosphamide (PTCy) in first complete remission from 1065 young (<35 years) haploidentical (Haplo) donors (yHaplo) vs. 147 old (≥35 years) mismatched unrelated donors (oMMUD) (first comparison) and from 271 young (<35 years) MMUD (yMMUD) vs. 1315 old (≥35 years) Haplo donors (oHaplo) (second comparison).

View Article and Find Full Text PDF

Resistance to dual antiplatelet therapy (DAPT), including aspirin and clopidogrel, in patients who have undergone percutaneous coronary intervention (PCI) leads to the inability to prevent thrombotic complications. The present study aimed to evaluate early resistance to aspirin and clopidogrel in patients following PCI using the VerifyNow test and associated factors. A total of 50 patients diagnosed with acute coronary syndromes (ACS) who underwent emergency PCI and received DAPT were recruited in the present study.

View Article and Find Full Text PDF

Background: A lower dosage of tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukaemia (CML) has shown efficacy in managing short-term toxicity and maintaining a deep molecular response in patients who fail to achieve treatment-free remission.

Method: From over 700 patients with CML who were treated at two centres over the last three decades, this retrospective study identified eight patients characterised by long-term treatment failure and simultaneous prolonged significant haematologic toxicity that prevented the use of the standard tyrosine kinase inhibitor dosage.

Results: Patients had a high or intermediate ELTS risk score, and most had significant comorbidities.

View Article and Find Full Text PDF